Latest news indicates that US pharmaceutical giant Pfizer...Pfizer Inc. plans to sell its remaining stake in BioNTech SE, a COVID-19 vaccine partner.
　　Sources familiar with the matter revealed that Pfizer plans to sell approximately 4.55 million BioNTech American Depositary Receipts (ADRs) via overnight block trade, with a price range of $108 to $111.70 per share.
　　Based on the upper limit of the range, Pfizer could potentially raise approximately $508 million from this share sale. If this news is true, it would mark the "formal separation" of these two partners who were among the most profitable during the COVID-19 pandemic.
　　Following the news, BioNTech SE shares fell nearly 4.4% in pre-market trading, currently trading at $106.82 per share; Pfizer shares fell slightly by 0.4% to $25.75.
　　BioNTech was founded in 2008 and is headquartered in Mainz, Germany. It went public on Nasdaq in 2019.Going public.
　　In 2020, Pfizer partnered with BioNTech to develop a COVID-19 vaccine, and Pfizer's equity investment in BioNTech was part of the vaccine collaboration agreement. In late 2020, the U.S. Food and Drug Administration (FDA) approved the vaccine's Emergency Use Authorization application.
　　The FDA's endorsement secured large-scale procurement contracts from European and American governments for the vaccine, which contributed $37.806 billion in revenue to Pfizer in 2022. BioNTech's market capitalization once exceeded $100 billion, but failed to maintain this level for long, and is currently around $27 billion.
　　With the end of the COVID-19 pandemic, Pfizer's revenue has declined significantly, and the company urgently needs to find new growth drivers to compensate for the loss in its COVID-19 business. Last week, Pfizer offered $10 billion to acquire Metera, which was the deal with its competitor Novo Nordisk."Knowing when to retreat."
　　On the other hand, BioNTech has refocused on cancer treatment, using its accumulated funds to fund research. However, due to increased investment in clinical trials, BioNTech's stock price has fallen nearly 2% year-to-date.

https://finance.eastmoney.com/a/202511133563815396.html